Jason M Jussif, 54125 Arlington St, Haverhill, MA 01830
Jason Jussif Phones & Addresses
125 Arlington St, Haverhill, MA 01830
26 Highland St, Hudson, NH 03051
24 Policy St, Salem, NH 03079 603-5530173
7 Webster St, Salem, NH 03079
24 N Policy St, Salem, NH 03079
Mentions for Jason M Jussif
Publications & IP owners
Us Patents
Methods Of Upmodulating Adaptive Immune Response Using Anti-Pd-1 Antibodies
US Patent:
7521051, Apr 21, 2009
Filed:
Dec 22, 2003
Appl. No.:
10/540084
Inventors:
Mary Collins - Natick MA, US
Clive R. Wood - Boston MA, US
Beatriz M. Carreno - Acton MA, US
Deborah Luxenberg - Melrose MA, US
Jason Jussif - Salem NH, US
Laura L. Carter - Medford MA, US
Frances K. Bennett - Sudbury MA, US
Viia Valge-Archer - Little Abington, GB
John Andrews - Ware, GB
Caroline Russell - Royston, GB
Clive R. Wood - Boston MA, US
Beatriz M. Carreno - Acton MA, US
Deborah Luxenberg - Melrose MA, US
Jason Jussif - Salem NH, US
Laura L. Carter - Medford MA, US
Frances K. Bennett - Sudbury MA, US
Viia Valge-Archer - Little Abington, GB
John Andrews - Ware, GB
Caroline Russell - Royston, GB
Assignee:
MedImmune Limited - Cambridge
Wyeth - Madison NJ
Wyeth - Madison NJ
International Classification:
A61K 39/395
US Classification:
4241441, 4241301, 4241411, 4241421, 4241431
Abstract:
This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.
Nucleic Acids Encoding Antibodies Against Pd-1
US Patent:
8088905, Jan 3, 2012
Filed:
Mar 16, 2009
Appl. No.:
12/405058
Inventors:
Mary Collins - Natick MA, US
Clive R. Wood - Boston MA, US
Beatriz M. Carreno - Acton MA, US
Deborah Luxenberg - Melrose MA, US
Jason Jussif - Salem NH, US
Laura L. Carter - Medford MA, US
Frances K. Bennett - Sudbury MA, US
Viia Valge-Archer - Little Abbington, GB
John Andrews - Little Hadham Ware, GB
Caroline Russell - Herts, GB
Clive R. Wood - Boston MA, US
Beatriz M. Carreno - Acton MA, US
Deborah Luxenberg - Melrose MA, US
Jason Jussif - Salem NH, US
Laura L. Carter - Medford MA, US
Frances K. Bennett - Sudbury MA, US
Viia Valge-Archer - Little Abbington, GB
John Andrews - Little Hadham Ware, GB
Caroline Russell - Herts, GB
Assignee:
Wyeth - Madison NJ
MedImmune Limited
MedImmune Limited
International Classification:
C12N 15/11
US Classification:
536 231
Abstract:
This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.
Antibodies Against Pd-1 And Uses Therefor
US Patent:
2004021, Oct 28, 2004
Filed:
Dec 22, 2003
Appl. No.:
10/741481
Inventors:
Mary Collins - Natick MA, US
Clive Wood - Boston MA, US
Beatriz Carreno - Acton MA, US
Deborah Luxenberg - Melrose MA, US
Jason Jussif - Salem NH, US
Laura Carter - Medford MA, US
Frances Bennett - Sudbury MA, US
Viia Valge-Archer - Little Abington, GB
John Andrews - Little Hadham Ware, GB
Caroline Russell - Royston, GB
Clive Wood - Boston MA, US
Beatriz Carreno - Acton MA, US
Deborah Luxenberg - Melrose MA, US
Jason Jussif - Salem NH, US
Laura Carter - Medford MA, US
Frances Bennett - Sudbury MA, US
Viia Valge-Archer - Little Abington, GB
John Andrews - Little Hadham Ware, GB
Caroline Russell - Royston, GB
International Classification:
A61K039/395
C07K016/30
C07K016/30
US Classification:
424/155100, 530/388800
Abstract:
This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.
Antibodies Against Pd-1 And Uses Therefor
US Patent:
2008031, Dec 18, 2008
Filed:
Aug 17, 2007
Appl. No.:
11/893989
Inventors:
Mary Collins - Natick MA, US
Clive R. Wood - Boston MA, US
Beatriz M. Carreno - Acton MA, US
Deborah Luxenberg - Melrose MA, US
Jason Jussif - Salem NH, US
Laura L. Carter - Medford MA, US
Frances K. Bennett - Sudbury MA, US
Viia Valge-Archer - Little Abington, GB
John Andrews - Little Hadham Ware, GB
Caroline Russell - Royston, GB
Clive R. Wood - Boston MA, US
Beatriz M. Carreno - Acton MA, US
Deborah Luxenberg - Melrose MA, US
Jason Jussif - Salem NH, US
Laura L. Carter - Medford MA, US
Frances K. Bennett - Sudbury MA, US
Viia Valge-Archer - Little Abington, GB
John Andrews - Little Hadham Ware, GB
Caroline Russell - Royston, GB
International Classification:
A61K 39/395
A61P 35/00
A61P 35/00
US Classification:
4241331, 4241301, 4241391, 4241731
Abstract:
This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.
NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.